JP2018535394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018535394A5 JP2018535394A5 JP2018514414A JP2018514414A JP2018535394A5 JP 2018535394 A5 JP2018535394 A5 JP 2018535394A5 JP 2018514414 A JP2018514414 A JP 2018514414A JP 2018514414 A JP2018514414 A JP 2018514414A JP 2018535394 A5 JP2018535394 A5 JP 2018535394A5
- Authority
- JP
- Japan
- Prior art keywords
- lcn2
- patient
- disease
- level
- levels
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021110695A JP7153775B2 (ja) | 2015-09-17 | 2021-07-02 | Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測 |
| JP2022159196A JP2023002583A (ja) | 2015-09-17 | 2022-10-03 | Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562220062P | 2015-09-17 | 2015-09-17 | |
| US62/220,062 | 2015-09-17 | ||
| PCT/US2016/052060 WO2017049035A1 (en) | 2015-09-17 | 2016-09-16 | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021110695A Division JP7153775B2 (ja) | 2015-09-17 | 2021-07-02 | Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018535394A JP2018535394A (ja) | 2018-11-29 |
| JP2018535394A5 true JP2018535394A5 (cg-RX-API-DMAC7.html) | 2020-11-12 |
| JP6909208B2 JP6909208B2 (ja) | 2021-07-28 |
Family
ID=58289919
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018514414A Expired - Fee Related JP6909208B2 (ja) | 2015-09-17 | 2016-09-16 | Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測 |
| JP2021110695A Expired - Fee Related JP7153775B2 (ja) | 2015-09-17 | 2021-07-02 | Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測 |
| JP2022159196A Pending JP2023002583A (ja) | 2015-09-17 | 2022-10-03 | Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021110695A Expired - Fee Related JP7153775B2 (ja) | 2015-09-17 | 2021-07-02 | Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測 |
| JP2022159196A Pending JP2023002583A (ja) | 2015-09-17 | 2022-10-03 | Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11016099B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3349854A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6909208B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180063127A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116672446A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016323579A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018005175A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2998349A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1258292A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL257969A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018003376A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2018113694A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017049035A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| WO2016054038A1 (en) | 2014-09-29 | 2016-04-07 | Immusant, Inc. | Use of hla genetic status to assess or select treatment of celiac disease |
| MX2018003376A (es) | 2015-09-17 | 2018-08-15 | Amgen Inc | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. |
| TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
| WO2019113037A1 (en) * | 2017-12-04 | 2019-06-13 | Immusant, Inc. | Measurement of ccl20 after gluten exposure |
| JP7901967B2 (ja) * | 2017-12-07 | 2026-08-07 | アムジエン・インコーポレーテツド | 特発性血小板減少症紫斑病(itp)をロミプロスチムで治療する方法 |
| JP7516250B2 (ja) * | 2018-03-05 | 2024-07-16 | ヤンセン バイオテツク,インコーポレーテツド | 抗il-23特異的抗体を用いたクローン病の治療方法 |
| WO2019220412A2 (en) * | 2018-05-18 | 2019-11-21 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-il12/il23 antibody |
| WO2020016838A2 (en) * | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained response predictors after treatment with anti-il23 specific antibody |
| HUE063462T2 (hu) * | 2018-09-24 | 2024-01-28 | Janssen Biotech Inc | A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel |
| EP3884276A2 (en) * | 2018-11-23 | 2021-09-29 | Katholieke Universiteit Leuven | Predicting a treatment response in inflammatory bowel disease |
| CN109337974B (zh) * | 2018-12-14 | 2022-01-25 | 北京蛋白质组研究中心 | 一种检测银屑病的诊断标志物的试剂及其应用 |
| WO2020128864A1 (en) * | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-il12/il23 antibody |
| MX2021011328A (es) * | 2019-03-18 | 2021-12-10 | Janssen Biotech Inc | Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23. |
| EP3946592A4 (en) * | 2019-03-26 | 2023-01-04 | Astrazeneca Collaboration Ventures, LLC | PATIENT POPULATIONS LIKELY TO BENEFIT FROM IL23 ANTAGONIST THERAPY |
| US20230096620A1 (en) * | 2019-04-17 | 2023-03-30 | Millennium Pharmaceuticals, Inc. | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy |
| EP3972690A4 (en) | 2019-05-23 | 2023-07-05 | Janssen Biotech, Inc. | METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA |
| JP2022544992A (ja) * | 2019-08-21 | 2022-10-24 | アストラゼネカ・コラボレイション・ベンチャーズ・リミテッド・ライアビリティ・カンパニー | クローン病を治療するためのブラジクマブの使用 |
| EP4045085A4 (en) * | 2019-10-18 | 2023-11-15 | Janssen Biotech, Inc. | SAFE AND EFFECTIVE METHOD OF TREATING ULCERATIVE COLITIS WITH ANTI-IL12/IL23 ANTIBODIES |
| EP4067372A4 (en) * | 2019-11-29 | 2023-11-08 | Toyobo Co., Ltd. | RECOMBINANT C-REACTIVE PROTEIN |
| CA3164996A1 (en) * | 2019-12-20 | 2021-06-14 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
| IL295545A (en) * | 2020-02-14 | 2022-10-01 | Janssen Biotech Inc | Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody |
| CN111424086A (zh) * | 2020-03-19 | 2020-07-17 | 上海交通大学 | 用于胃癌诊断及预后评估的生物标记物及应用和检测试剂盒 |
| US20230152314A1 (en) * | 2020-04-10 | 2023-05-18 | The Johns Hopkins University | Lipocalin-2 assay for intestinal adaptation |
| CA3183927A1 (en) | 2020-05-21 | 2021-11-25 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| MX2023004724A (es) * | 2020-10-23 | 2024-02-23 | Hq Han | Antagonistas bifuncionales de la activina y del factor alfa de necrosis tumoral y usos de los mismos. |
| KR20230165746A (ko) | 2020-11-30 | 2023-12-05 | 민데라 코포레이션 | 마이크로니들 디바이스 및 방법, 및 피부 병태 어세이 |
| US20220373539A1 (en) * | 2021-05-24 | 2022-11-24 | Amgen Inc. | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
| AU2025218720A1 (en) | 2024-02-06 | 2026-05-21 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
| WO2025171006A1 (en) | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 binding protein compositions and methods of use |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8318754D0 (en) | 1983-07-11 | 1983-08-10 | Fagerhol M K F | Human proteins anti-sera test kits |
| US5455160A (en) | 1993-05-27 | 1995-10-03 | Fagerhol; Magne K. | Diagnostic test and kit for disease or disorders in the digestive system |
| DE69731103T2 (de) | 1996-11-01 | 2005-11-17 | Fagerhol, Magne K., Dr. | Verfahren zur proteinextraktion |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ZA986596B (en) | 1997-07-25 | 1999-02-08 | Schering Corp | Mammalian cytokine related reagents |
| US7226591B2 (en) | 2000-05-22 | 2007-06-05 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| DK1311679T3 (da) | 2000-08-24 | 2009-02-23 | Genentech Inc | Fremgangsmåde til inhibering af IL-22-induceret PAP1 |
| EP1756138A4 (en) | 2004-03-05 | 2009-07-01 | Archemix Corp | APTAMERS FACILITATED TO THE FAMILY OF HUMAN IL-12 CYTOKINS AND THEIR USE AS THERAPEUTICS AGAINST AUTOIMMUNE DISEASES |
| CA2565701A1 (en) | 2004-05-06 | 2005-11-17 | Jonathan M. Barasch | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| KR100681763B1 (ko) | 2005-02-28 | 2007-02-15 | 재단법인 목암생명공학연구소 | 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법 |
| CA2613818C (en) | 2005-06-30 | 2013-08-27 | Centocor, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
| SI1937721T1 (sl) | 2005-08-25 | 2010-11-30 | Lilly Co Eli | Anti il protitelesa |
| ME02705B (me) | 2005-08-31 | 2017-10-20 | Merck Sharp & Dohme | Inženjerisana anti-il-23 antitela |
| DE602006009834D1 (de) | 2005-09-01 | 2009-11-26 | Schering Corp | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung |
| SI3219328T1 (sl) | 2005-12-29 | 2020-10-30 | Janssen Biotech, Inc. | Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe |
| US20070203216A1 (en) | 2006-02-14 | 2007-08-30 | Bjarke Ebert | Method of treating inflammatory diseases |
| WO2007098065A2 (en) | 2006-02-17 | 2007-08-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Human sodium channel isoforms |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス, インコーポレイテッド | Il−17およびil−23アンタゴニストならびにその使用方法 |
| CN101472611A (zh) | 2006-06-19 | 2009-07-01 | 惠氏公司 | 调节il-22和il-17的方法 |
| GB0613470D0 (en) | 2006-07-06 | 2006-08-16 | Ares Trading Sa | Protein |
| US7943310B2 (en) | 2006-08-30 | 2011-05-17 | Centocor Ortho Biotech Inc. | Methods for assessing response to therapy in subjects having ulcerative colitis |
| CN103396489A (zh) | 2007-02-23 | 2013-11-20 | 默沙东公司 | 工程改造的抗IL-23p19抗体 |
| HUE042172T2 (hu) | 2007-02-23 | 2019-06-28 | Merck Sharp & Dohme | Genetikailag elõállított anti-il-23P19 antitestek |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| US20090269777A1 (en) | 2007-10-19 | 2009-10-29 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| US20090123946A1 (en) | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| EP2225268B1 (en) | 2007-10-19 | 2012-08-29 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| EP2215481B2 (en) | 2007-11-15 | 2017-01-18 | Bioporto Diagnostics A/S | Diagnostic use of individual molecular forms of a biomarker |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| KR20100124326A (ko) | 2008-03-14 | 2010-11-26 | 엑사젠 다이어그노스틱스, 인코포레이티드 | 염증성 장 질병 및 과민성 장 증후군에 대한 생체마커 |
| US20100227775A1 (en) | 2008-04-16 | 2010-09-09 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| WO2010027766A1 (en) | 2008-08-27 | 2010-03-11 | Schering Corporation | Lyophilized formulatons of engineered anti-il-23p19 antibodies |
| GB2464183A (en) | 2008-09-19 | 2010-04-14 | Singulex Inc | Sandwich assay |
| EP2347256A4 (en) | 2008-10-09 | 2012-02-08 | Alfagene Bioscience Inc | USE AND IDENTIFY BIOMARKERS FOR STOMACH DISEASES |
| US20100105150A1 (en) | 2008-10-24 | 2010-04-29 | Abbott Laboratories | Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal |
| EP2352762A1 (en) | 2008-11-03 | 2011-08-10 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| WO2010115786A1 (en) | 2009-04-01 | 2010-10-14 | Glaxo Group Limited | Anti-il-23 immunoglobulins |
| WO2010129964A1 (en) | 2009-05-08 | 2010-11-11 | The Board Of Trustees Of The University Of Illinois | Drug targets for prevention of arrhythmia in heart disease |
| WO2010142534A1 (en) | 2009-05-27 | 2010-12-16 | Ablynx Nv | Biparatopic protein constructs directed against il-23 |
| ES2509616T3 (es) | 2009-06-25 | 2014-10-17 | Nestec S.A. | Procedimientos de diagnóstico del síndrome del intestino irritable |
| EP2451969A2 (en) | 2009-07-07 | 2012-05-16 | University Of Southern California | Biomarkers for the early detection of autoimmune diseases |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| CA2781654A1 (en) | 2009-11-25 | 2011-06-03 | Hua Gong | Novel genomic biomarkers for irritable bowel syndrome diagnosis |
| SI2523688T1 (en) | 2010-01-15 | 2018-03-30 | Kirin-Amgen, Inc. | Formulation of antibodies and therapeutic regimes |
| JP5972871B2 (ja) | 2010-07-20 | 2016-08-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗il−23ヘテロ二量体特異的抗体 |
| US8541180B1 (en) | 2010-10-11 | 2013-09-24 | Genova Diagnostics, Inc. | Compositions and methods for assessing gastrointestinal health |
| KR102049223B1 (ko) * | 2010-11-04 | 2019-11-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-il-23 항체 |
| JP6116485B2 (ja) | 2011-01-06 | 2017-04-19 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 心臓性突然死に関連する方法において使用するためのscn5aスプライスバリアント |
| GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
| US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
| JP2014507160A (ja) | 2011-02-22 | 2014-03-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス.アー.エール.エル. | 循環バイオマーカー |
| EP3825693A1 (en) | 2011-04-29 | 2021-05-26 | Cancer Prevention And Cure, Ltd. | Methods of identification and diagnosis of lung diseases using classification systems and kits thereof |
| EP2710383B1 (en) | 2011-05-16 | 2017-01-11 | The University of Newcastle | Performance of a biomarker panel for irritable bowel syndrome |
| NO336551B1 (no) | 2011-06-21 | 2015-09-28 | Magne Fagerhol | Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve |
| NO20110895A1 (no) | 2011-06-21 | 2012-12-24 | Magne Fagerhol | Kompetitive S100A9 immunoanalyser |
| CN103874770A (zh) | 2011-08-08 | 2014-06-18 | 卡里斯生命科学卢森堡控股有限责任公司 | 生物标志物组合物和方法 |
| WO2013116657A1 (en) * | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| WO2013132338A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Competitive immunoassay for calprotectin |
| WO2013132347A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Improved elisa immunoassay for calprotectin |
| WO2013152114A1 (en) | 2012-04-03 | 2013-10-10 | The Regents Of The University Of Michigan | Biomarker associated with irritable bowel syndrome and crohn's disease |
| KR101850591B1 (ko) * | 2012-10-05 | 2018-04-19 | 제넨테크, 인크. | 염증성 장 질환의 진단 및 치료 방법 |
| KR102757668B1 (ko) | 2014-05-15 | 2025-01-21 | 메소 스케일 테크놀러지즈, 엘엘시 | 개선된 분석 방법 |
| WO2015191783A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| EP3172339A1 (en) * | 2014-07-24 | 2017-05-31 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| MX2018003376A (es) | 2015-09-17 | 2018-08-15 | Amgen Inc | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. |
| GB201521357D0 (en) | 2015-12-03 | 2016-01-20 | Univ Liverpool | Methods for predicting response to anti-TNF therapy |
| WO2017112536A1 (en) | 2015-12-22 | 2017-06-29 | Amgen Inc. | Ccl20 as a predictor of clinical response to il23-antagonists |
| US20200064357A1 (en) | 2016-11-09 | 2020-02-27 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
| WO2018119626A1 (zh) | 2016-12-27 | 2018-07-05 | 菲鹏生物股份有限公司 | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
-
2016
- 2016-09-16 MX MX2018003376A patent/MX2018003376A/es unknown
- 2016-09-16 EP EP16847353.6A patent/EP3349854A4/en not_active Withdrawn
- 2016-09-16 HK HK19100656.4A patent/HK1258292A1/zh unknown
- 2016-09-16 RU RU2018113694A patent/RU2018113694A/ru not_active Application Discontinuation
- 2016-09-16 US US15/759,330 patent/US11016099B2/en active Active
- 2016-09-16 AU AU2016323579A patent/AU2016323579A1/en not_active Abandoned
- 2016-09-16 KR KR1020187010308A patent/KR20180063127A/ko not_active Withdrawn
- 2016-09-16 CA CA2998349A patent/CA2998349A1/en not_active Abandoned
- 2016-09-16 JP JP2018514414A patent/JP6909208B2/ja not_active Expired - Fee Related
- 2016-09-16 CN CN202310427386.3A patent/CN116672446A/zh active Pending
- 2016-09-16 CN CN201680066986.XA patent/CN108290058B/zh not_active Expired - Fee Related
- 2016-09-16 BR BR112018005175A patent/BR112018005175A2/pt not_active Application Discontinuation
- 2016-09-16 WO PCT/US2016/052060 patent/WO2017049035A1/en not_active Ceased
-
2018
- 2018-03-08 IL IL257969A patent/IL257969A/en unknown
-
2021
- 2021-07-02 JP JP2021110695A patent/JP7153775B2/ja not_active Expired - Fee Related
-
2022
- 2022-10-03 JP JP2022159196A patent/JP2023002583A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7153775B2 (ja) | Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測 | |
| JP2019508370A5 (cg-RX-API-DMAC7.html) | ||
| JP6849751B2 (ja) | 可溶性ヒトst−2抗体およびアッセイ法 | |
| US8828668B2 (en) | Markers for determination of patient responsiveness | |
| RU2018124603A (ru) | Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23 | |
| RU2016134838A (ru) | Дипептидил пептидаза-4 (dpp4/cd26) как периферический биомаркер активации il-13 в астматическом легком | |
| RU2016135417A (ru) | Новый анализ для детектирования периостина человека | |
| TWI655433B (zh) | 川崎氏症之診斷與治療 | |
| EP4587840A1 (en) | Hbv diagnostic, prognostic, and therapeutic methods and products | |
| US12624397B2 (en) | Biomarkers associated with anti-IL-36R antibody treatment in generalized pustular psoriasis | |
| Fouladseresht et al. | Anti-varicella zoster virus IgG and hsCRP levels correlate with progression of coronary artery atherosclerosis | |
| Eder et al. | Association of serum VEGF with clinical response to anti-TNFα therapy for Crohn’s disease | |
| Mukherjee et al. | IL-13 signature in severe adult asthmatics with airway neutrophilia: A new endotype to treat! | |
| CN116323654A (zh) | 涉及il-18的抗体的方法及疗法 | |
| WO2015166461A1 (en) | Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels | |
| Guerra et al. | Measurement of anti-TNF agents and anti-drug antibodies serum levels in patients with inflammatory bowel disease | |
| Tanapon Ussanawarong et al. | The Immunogenicity of SARS-CoV-2 Vaccines in Thai Patients with Rheumatoid Arthritis: A Cross-Sectional Study from the National Health Thailand Program | |
| WO2026058045A1 (en) | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy | |
| Nerella et al. | Demystifying the three different types of COVID-19 associated multisystem inflammatory syndrome in children: Experience from a tertiary care hospital |